[HTML][HTML] A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive …
K Goto, M Nishio, N Yamamoto, K Chikamori, T Hida… - Lung Cancer, 2013 - Elsevier
Introduction The epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor erlotinib
is associated with survival benefits in patients with EGFR mutation-positive non-small-cell …
is associated with survival benefits in patients with EGFR mutation-positive non-small-cell …
Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim …
R Rosell, R Gervais, A Vergnenegre… - Journal of clinical …, 2011 - ascopubs.org
7503 Background: EGFR tyrosine kinase activating mutations are present in 10-26% of
NSCLC tumors and are associated with increased response to gefitinib and erlotinib …
NSCLC tumors and are associated with increased response to gefitinib and erlotinib …
Prospective evaluation of first-line erlotinib in advanced non-small cell lung cancer (NSCLC) carrying an activating EGFR mutation: A multicenter academic phase II …
J De Grève, J Van Meerbeeck, JF Vansteenkiste… - PLoS …, 2016 - journals.plos.org
Introduction Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibition is the
preferred first-line treatment of advanced adenocarcinoma of the lung that harbors EGFR …
preferred first-line treatment of advanced adenocarcinoma of the lung that harbors EGFR …
[HTML][HTML] A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama …
H Yoshioka, K Hotta, K Kiura, N Takigawa… - Journal of Thoracic …, 2010 - Elsevier
Backgrounds Efficacy of gefitinib therapy strongly depends on epidermal growth factor
receptor (EGFR)-mutation status in Asian patients with non-small cell lung cancer. Recently …
receptor (EGFR)-mutation status in Asian patients with non-small cell lung cancer. Recently …
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a …
C Zhou, YL Wu, G Chen, J Feng, XQ Liu… - The lancet …, 2011 - thelancet.com
Background Activating mutations in EGFR are important markers of response to tyrosine
kinase inhibitor (TKI) therapy in non-small-cell lung cancer (NSCLC). The OPTIMAL study …
kinase inhibitor (TKI) therapy in non-small-cell lung cancer (NSCLC). The OPTIMAL study …
[HTML][HTML] First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III …
Background The phase III, randomized, open-label ENSURE study (NCT01342965)
evaluated first-line erlotinib versus gemcitabine/cisplatin (GP) in patients from China …
evaluated first-line erlotinib versus gemcitabine/cisplatin (GP) in patients from China …
First-line erlotinib therapy until and beyond response evaluation criteria in solid tumors progression in Asian patients with epidermal growth factor receptor mutation …
K Park, CJ Yu, SW Kim, MC Lin, V Sriuranpong… - JAMA …, 2016 - jamanetwork.com
Importance Continuing molecularly targeted treatment beyond disease progression in non–
small-cell lung cancer (NSCLC) has appeared promising in retrospective analyses …
small-cell lung cancer (NSCLC) has appeared promising in retrospective analyses …
[HTML][HTML] Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer …
N Yamamoto, T Seto, M Nishio, K Goto, I Okamoto… - Lung Cancer, 2021 - Elsevier
Abstract Objectives The JO25567 randomized Phase II study demonstrated a statistically
significant progression-free survival (PFS) benefit with erlotinib plus bevacizumab compared …
significant progression-free survival (PFS) benefit with erlotinib plus bevacizumab compared …
Erlotinib in wild type epidermal growth factor receptor non-small cell lung cancer: A systematic review
AR Jazieh, R Al Sudairy, N Abu-Shraie… - Annals of thoracic …, 2013 - journals.lww.com
BACKGROUND: Targeting epidermal growth factor receptors (EGFR) is an innovative
approach to managing non-small cell lung cancer (NSCLC) which harbors EGFR mutation …
approach to managing non-small cell lung cancer (NSCLC) which harbors EGFR mutation …
[HTML][HTML] Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations
Purpose The tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib are effective in non-small
cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) gene mutations …
cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) gene mutations …